HGH Fragment 176-191 vs AOD 9604: What's the Difference?

HGH Fragment 176-191 and AOD 9604 are not competing peptides from different laboratories — AOD 9604 is a modified version of the same region of human growth hormone. The main difference is that HGH Fragment 176-191 is the native sequence, while AOD 9604 is a stabilized analog built from residues 177-191 with an added tyrosine at the front end. Neither peptide is FDA-approved for human use in the United States, and both are banned in competitive sport.

Are HGH Fragment 176-191 and AOD 9604 the Same Peptide?

They come from the same place, but they are not identical molecules. HGH Fragment 176-191 is the natural C-terminal tail of growth hormone, a chain of 16 amino acids that researchers identified as the part of the hormone tied to fat breakdown. AOD 9604 is an engineered version of that region: it uses residues 177-191 and adds a tyrosine to make the peptide more stable in the body.

That single design change explains most of the practical gap between them. When people search aod 9604 vs hgh frag 176 191, they are usually asking whether a stabilized analog behaves differently from the native fragment. The honest answer is that the claimed effect is the same — the half-life and the handling are what change.

HGH Fragment 176-191 vs AOD 9604: Side-by-Side Comparison

Feature	HGH Fragment 176-191	AOD 9604
What it is	Native C-terminal sequence of hGH (residues 176-191)	Engineered analog of residues 177-191 with an added N-terminal tyrosine
Other names	hGH 176-191, HGH Frag	AOD-9604, Tyr-hGH177-191
Stability	Short half-life; breaks down quickly	Modified for greater stability and slower clearance
Human trial record	Limited; mostly lab and animal data plus small studies	Multiple Phase I and Phase II human trials as an obesity drug candidate
Development outcome	Never taken through formal drug development	Weight loss was statistically significant but modest; the obesity program was discontinued
FDA status	Not approved for human use	Not approved as a drug; has appeared in supplement products the FDA has challenged
WADA status	Banned as a GH releasing peptide	Banned and named explicitly on the prohibited list
Typical forms sold	Lyophilized powder for research use	Lyophilized powder, capsules, and topical gels

The table above is the short version: AOD 9604 is essentially HGH Fragment 176-191 with better staying power and a real, if disappointing, clinical trial history.

Research History: Which Peptide Has More Human Data?

AOD 9604 has the stronger paper trail. It was developed in Australia as an anti-obesity drug and tested in humans across several trials in the 1990s and 2000s. Participants did lose weight, and the results were statistically significant, but the effect size was modest.

HGH Fragment 176-191 has far less human data. Most published work looks at fat cells in culture or at animal models, where the fragment appears to stimulate lipolysis without raising IGF-1 or disrupting blood sugar.

Neither peptide ever earned regulatory approval for weight loss. AOD 9604's development program was shelved after later results fell short of what an obesity approval would require.

Claimed Benefits vs. What the Evidence Shows

hgh fragment 176 191 benefits most often described in research summaries center on fat metabolism rather than muscle growth. The peptide is studied as a lipolytic agent — something that helps fat cells release stored energy — and it is generally reported not to affect IGF-1 or glucose the way full-length growth hormone does.

AOD 9604 is marketed with nearly identical claims: fat loss, no water retention, no impact on blood sugar. The two profiles overlap so closely that shoppers often cannot tell which compound a vendor is actually selling.

It is worth separating marketing from evidence here. No large, independent trial has demonstrated meaningful fat loss in healthy adults using the peptides sold online, and hgh fragment 176-191 vs somatropin is a completely different conversation, because somatropin is a prescription drug with far broader effects on the body.

Dosing, Forms, and Stability

There is no established human dose for either peptide outside of research settings. Published AOD 9604 trials used daily subcutaneous injections in milligram amounts, and that program never produced an approved product. Online protocols vary widely and are not a reliable substitute for clinical guidance.

The formats differ in a practical way:

• HGH Fragment 176-191 is almost always sold as a lyophilized powder that must be reconstituted and injected.
• AOD 9604 is sold as powder, but also in capsules and topical gels, which are easier to use but supported by very little absorption data.

Stability is the reason AOD 9604 exists in the first place. The native fragment degrades quickly, so more frequent administration is usually assumed, while the analog was designed to circulate longer. Cold-chain storage and careful handling matter for both.

Safety, Legal Status, and the Bottom Line

Neither compound is FDA-approved for human use, and neither should be treated as a proven weight-loss treatment. Side effects reported anecdotally in research-peptide circles include injection-site irritation, headache, and fatigue, but long-term human safety data is essentially absent.

Both peptides sit on the World Anti-Doping Agency prohibited list, and anti-doping laboratories test for them.

aod 9604 vs tesamorelin makes a useful contrast, because tesamorelin is one of the few peptides in this family with an actual FDA approval — for reducing excess visceral fat in adults with HIV-associated lipodystrophy. That approval covers tesamorelin only and says nothing about AOD 9604 or HGH Fragment 176-191. aod 9604 vs mots-c is another common comparison, though MOTS-c works through a different metabolic pathway and is not a growth hormone fragment at all.

The practical takeaway: AOD 9604 is the stabilized, better-studied version of HGH Fragment 176-191, and the two are close enough that many sources treat them as interchangeable. What they are not is approved medicine, and anyone considering either one should talk with a healthcare professional first.

COMMON QUESTIONS

Frequently Asked Questions

Is AOD 9604 the same as HGH Fragment 176-191?

They are closely related but not identical. AOD 9604 is a modified form of the same region of human growth hormone, using residues 177-191 with an added tyrosine for stability, while HGH Fragment 176-191 is the native 176-191 sequence. Both are studied for fat metabolism, and neither is FDA-approved for human use.

Which is better for fat loss, AOD 9604 or HGH Fragment 176-191?

Neither has been shown to produce meaningful fat loss in large, independent human trials. AOD 9604 went through Phase I and Phase II testing and produced statistically significant but modest weight loss, and its obesity development program was discontinued. HGH Fragment 176-191 has less human data, so there is no evidence-based way to rank them.

Is HGH Fragment 176-191 or AOD 9604 legal in the United States?

Neither peptide is FDA-approved for human use in the United States, and both are banned by the World Anti-Doping Agency. They are typically sold as research chemicals, not as supplements or medicines, and the FDA has challenged companies that put AOD 9604 into dietary supplement products. Buying either one for personal injection use is not a legally sanctioned use.